Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Histrelin Implant in Advanced Prostate Cancer
NCT01697384Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Apr 2000
- Primary completion
- Aug 2003
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of histrelin in prostate cancer (PCa), sponsored by Endo International plc. Primary endpoint: Suppression of testosterone to chemical castration levels (<= 50 ng/dL) at 52 weeks. Started Apr 2000; status: completed.
02
Drugs
histrelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01697384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697384.